Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Acquired Resistance to Decitabine Associated with the Deoxycytidine Kinase A180P Mutation: Implications for the Order of Hypomethylating Agents in Myeloid Malignancies Treatment

K. Simonicova, L. Janotka, H. Kavcova, I. Borovska, Z. Sulova, A. Breier, L. Messingerova

. 2025 ; 26 (11) : . [pub] 20250525

Language English Country Switzerland

Document type Journal Article

Grant support
APVV-19-0093 Slovak Agency for Research and Development
APVV-19-0094 Slovak Agency for Research and Development
VEGA 2/0016/22 Grant Agency of the Ministry of Education of the Slovak Republic and the Slovak Academy of Sciences
CA21154 project MVTS

The backbone of therapy for elderly patients with myelodysplastic syndromes and acute myeloid leukemia consists of hypomethylating agents 5-aza-2'-deoxycytidine (DAC) and 5-azacytidine (AZA). However, resistance frequently emerges during treatment. To investigate the mechanisms of resistance, we generated DAC-resistant variants of the acute myeloid leukemia cell lines, MOLM-13 and SKM-1, through their prolonged cultivation in increasing concentrations of DAC. The resistant cell variants, MOLM-13/DAC and SKM-1/DAC, exhibited cross-resistance to cytarabine and gemcitabine, but remained sensitive to AZA. Existing studies have suggested that the loss of deoxycytidine kinase (DCK) may play an important role in DAC resistance. DCK is critical for DAC activation, but the precise mechanisms of its downregulation remain incompletely understood. We identified a novel point mutation (A180P) in DCK, which results in acquired DAC resistance. Although the DCK mRNA was actively transcribed, the mutant protein was not detected in DAC-resistant cells. The transfection of HEK293 cells with the mutant DCK, combined with proteasomal inhibition, revealed rapid proteasomal degradation, establishing a mechanistic link between the A180P mutation and DCK loss, not previously described. This highlights the importance of also evaluating DCK at the protein and/or enzymatic activity levels in patients. The loss of functional DCK impairs the phosphorylation of deoxynucleosides, conferring resistance to DAC, gemcitabine, and cytarabine, but AZA, phosphorylated by uridine-cytidine kinase, remains effective and may represent a therapeutic alternative for patients with acquired DAC resistance.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015662
003      
CZ-PrNML
005      
20250731091144.0
007      
ta
008      
250708s2025 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms26115083 $2 doi
035    __
$a (PubMed)40507894
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Simonicova, Kristina $u Institute of Molecular Physiology and Genetics, Centre of Biosciences, Slovak Academy of Sciences, Dúbravská cesta 9, 840 05 Bratislava, Slovakia $1 https://orcid.org/0009000443181080
245    10
$a Acquired Resistance to Decitabine Associated with the Deoxycytidine Kinase A180P Mutation: Implications for the Order of Hypomethylating Agents in Myeloid Malignancies Treatment / $c K. Simonicova, L. Janotka, H. Kavcova, I. Borovska, Z. Sulova, A. Breier, L. Messingerova
520    9_
$a The backbone of therapy for elderly patients with myelodysplastic syndromes and acute myeloid leukemia consists of hypomethylating agents 5-aza-2'-deoxycytidine (DAC) and 5-azacytidine (AZA). However, resistance frequently emerges during treatment. To investigate the mechanisms of resistance, we generated DAC-resistant variants of the acute myeloid leukemia cell lines, MOLM-13 and SKM-1, through their prolonged cultivation in increasing concentrations of DAC. The resistant cell variants, MOLM-13/DAC and SKM-1/DAC, exhibited cross-resistance to cytarabine and gemcitabine, but remained sensitive to AZA. Existing studies have suggested that the loss of deoxycytidine kinase (DCK) may play an important role in DAC resistance. DCK is critical for DAC activation, but the precise mechanisms of its downregulation remain incompletely understood. We identified a novel point mutation (A180P) in DCK, which results in acquired DAC resistance. Although the DCK mRNA was actively transcribed, the mutant protein was not detected in DAC-resistant cells. The transfection of HEK293 cells with the mutant DCK, combined with proteasomal inhibition, revealed rapid proteasomal degradation, establishing a mechanistic link between the A180P mutation and DCK loss, not previously described. This highlights the importance of also evaluating DCK at the protein and/or enzymatic activity levels in patients. The loss of functional DCK impairs the phosphorylation of deoxynucleosides, conferring resistance to DAC, gemcitabine, and cytarabine, but AZA, phosphorylated by uridine-cytidine kinase, remains effective and may represent a therapeutic alternative for patients with acquired DAC resistance.
650    _2
$a lidé $7 D006801
650    12
$a decitabin $x farmakologie $7 D000077209
650    12
$a deoxycytidinkinasa $x genetika $x metabolismus $7 D003842
650    12
$a chemorezistence $x genetika $x účinky léků $7 D019008
650    _2
$a nádorové buněčné linie $7 D045744
650    12
$a protinádorové antimetabolity $x farmakologie $7 D000964
650    12
$a azacytidin $x farmakologie $x analogy a deriváty $7 D001374
650    _2
$a HEK293 buňky $7 D057809
650    12
$a akutní myeloidní leukemie $x genetika $x farmakoterapie $7 D015470
650    _2
$a mutace $7 D009154
650    _2
$a cytarabin $x farmakologie $7 D003561
650    _2
$a deoxycytidin $x analogy a deriváty $x farmakologie $7 D003841
655    _2
$a časopisecké články $7 D016428
700    1_
$a Janotka, Lubos $u Institute of Molecular Physiology and Genetics, Centre of Biosciences, Slovak Academy of Sciences, Dúbravská cesta 9, 840 05 Bratislava, Slovakia $u Department of Biology, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hnevotinska 3, 77515 Olomouc, Czech Republic
700    1_
$a Kavcova, Helena $u Institute of Molecular Physiology and Genetics, Centre of Biosciences, Slovak Academy of Sciences, Dúbravská cesta 9, 840 05 Bratislava, Slovakia
700    1_
$a Borovska, Ivana $u Institute of Molecular Physiology and Genetics, Centre of Biosciences, Slovak Academy of Sciences, Dúbravská cesta 9, 840 05 Bratislava, Slovakia $1 https://orcid.org/000000028090387X
700    1_
$a Sulova, Zdena $u Institute of Molecular Physiology and Genetics, Centre of Biosciences, Slovak Academy of Sciences, Dúbravská cesta 9, 840 05 Bratislava, Slovakia $1 https://orcid.org/0000000176034491
700    1_
$a Breier, Albert $u Institute of Molecular Physiology and Genetics, Centre of Biosciences, Slovak Academy of Sciences, Dúbravská cesta 9, 840 05 Bratislava, Slovakia $u Institute of Biochemistry and Microbiology, Faculty of Chemical and Food Technology, Slovak University of Technology in Bratislava, Radlinského 9, 812 37 Bratislava, Slovakia $1 https://orcid.org/000000032174786X $7 xx0194103
700    1_
$a Messingerova, Lucia $u Institute of Molecular Physiology and Genetics, Centre of Biosciences, Slovak Academy of Sciences, Dúbravská cesta 9, 840 05 Bratislava, Slovakia $u Institute of Biochemistry and Microbiology, Faculty of Chemical and Food Technology, Slovak University of Technology in Bratislava, Radlinského 9, 812 37 Bratislava, Slovakia $1 https://orcid.org/0000000279665560
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 26, č. 11 (2025)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40507894 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091138 $b ABA008
999    __
$a ok $b bmc $g 2366487 $s 1252787
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 26 $c 11 $e 20250525 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
GRA    __
$a APVV-19-0093 $p Slovak Agency for Research and Development
GRA    __
$a APVV-19-0094 $p Slovak Agency for Research and Development
GRA    __
$a VEGA 2/0016/22 $p Grant Agency of the Ministry of Education of the Slovak Republic and the Slovak Academy of Sciences
GRA    __
$a CA21154 project $p MVTS
LZP    __
$a Pubmed-20250708

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...